2023
Shared and Distinct Brain Regions Targeted for Immediate Early Gene Expression by Ketamine and Psilocybin
Davoudian P, Shao L, Kwan A. Shared and Distinct Brain Regions Targeted for Immediate Early Gene Expression by Ketamine and Psilocybin. ACS Chemical Neuroscience 2023, 14: 468-480. PMID: 36630309, PMCID: PMC9898239, DOI: 10.1021/acschemneuro.2c00637.Peer-Reviewed Original ResearchConceptsC-fos expressionBrain regionsNeural plasticityPlasticity-related gene expressionPrimary visual cortexNumerous brain regionsAnterior cingulate cortexExact brain regionsContribution of receptorsDistinct brain regionsImmediate early gene expressionDorsal rapheGlutamatergic receptorsCA1 subfieldSubanesthetic ketamineFemale miceLocus coeruleusInsular cortexSaline controlsTherapeutic effectPsilocybin administrationBasolateral amygdalaLateral habenulaCingulate cortexVisual cortex
2020
Chapter Four Clinical overview of NMDA-R antagonists and clinical practice
Davoudian PA, Wilkinson ST. Chapter Four Clinical overview of NMDA-R antagonists and clinical practice. Advances In Pharmacology 2020, 89: 103-129. PMID: 32616204, DOI: 10.1016/bs.apha.2020.04.004.ChaptersConceptsNMDA receptor antagonistReceptor antagonistGlutamatergic systemClinical trialsPathophysiology of depressionLevels of monoaminesNMDA-R antagonistsTreatment of depressionRole of glutamatePatient's therapeutic responseRecent FDA approvalIntranasal esketamineMonoamine hypothesisPathophysiological mechanismsClinical overviewTherapeutic responseCurrent treatmentClinical practiceTranslational studiesMental illnessFDA approvalNeural circuitsAntagonistDepressionPotential mechanisms